Summary

Biotech entered JPM at “five out of 10”: battered, with some investors seeing valuations as cheap, but not yet supported by broad capital. Mike Yee’s line that “the macro has the steering wheel” explained why deals produced little follow-through while generalists stayed concentrated in technology and the Magnificent 7. Investors may have priced in some interest-rate and RFK uncertainty, but Yee was “certainly not calling it a raging bull market.”
The IPO window remains discriminating, with Metsera’s obesity offering positioned as an important first test. Two private biotechs that likely might have floated instead accepted acquisitions, signaling how much leverage buyers retain. Metsera’s once-monthly GLP-1 concept addresses an enormous, underpenetrated market, but after two straight quarters of Lilly disappointment, the near-term question is whether a new entrant begins at a $600 million or $1 billion valuation—not whether obesity medicines ultimately create value.
J&J’s $14.6 billion acquisition of Intra-Cellular Therapies highlighted both CNS demand and the extraordinary payoff from surviving its clinical-development hazards. CAPLYTA is already approved for schizophrenia and bipolar depression, while a requested expansion into major depressive disorder would address roughly 10 times as many people as schizophrenia. Daphne Zohar put the asymmetry sharply: neuropsychiatry carries an estimated 93% failure rate from preclinical work to clinical proof of concept, yet a late-stage success can be “worth about $14 billion.”
The Intra-Cellular transaction also supplied a rare capital-efficiency benchmark: $1.22 billion raised across private and public markets versus a $14.6 billion exit. Citing Bruce Booth’s analysis, John Maraganore described approximately 13× value creation in less than 12 years and highlighted Sharon Mates’ unusually durable founder-CEO journey. Alongside BMS–Karuna and other multibillion-dollar CNS transactions, it shows that pharma remains willing to pay for clinically derisked neuroscience assets.
XBI is an increasingly imperfect proxy for the biotech opportunity set, masking a market of extreme “haves and have-nots.” Josh Schimmer’s observation that the average biotech rose last year even when XBI ended around 1% reflects an index that historically equal-weighted and rebalanced roughly 130 names every 90 days, then recently tilted toward market capitalization and liquidity. With XBI down roughly 3% early in 2025, stock selection mattered far more than the headline index.
China’s advantage is clinical speed and cost, and the clearest response may be to strengthen the U.S. system rather than try to wall off Chinese innovation. Nearly one-third of pharma’s externally sourced molecules and about $6 billion of licensing upfronts over the prior year were said to involve China; Merck’s $112 million upfront for Hansoh’s oral GLP-1 was followed by sharp falls in Structure Therapeutics and Viking. John Crowley argued that BIOSECURE would have limited direct effect: “What can we do to strengthen our ecosystem?” is the more consequential policy question.
FDA and trial reform could become the most important policy upside if safety standards are preserved while timelines compress. Crowley said more than 100 emerging-company CEOs converged on the same complaint—development “costs too much money, takes too much time, it’s too uncertain”—and advocated biomarkers, accelerated approval, adaptive designs and Bayesian statistics. John Connolly’s comparison was stark: a Penn cell-and-gene-therapy signal-finding study might take two years, during which “20 companies” could already have run the equivalent trial in China.

Deep dive

1. JPM exposed a market still governed by rates, not deal headlines

Mike Yee scored sentiment “about a five out of 10”: December and early January had already punished stocks, Monday and Tuesday were rough, and Wednesday brought only a modest rebound. His optimistic case was conditional—some investors viewed valuations as cheap, broader markets remained healthy and the administration might moderate its rhetoric—but he was “not calling it a raging bull market.”
Yee’s mechanism was that “the macro has the steering wheel.” Higher-for-longer rates and limited generalist participation leave specialists and hedge funds trading the same biotech inventory, while larger pools remain focused on technology and the Magnificent 7. Despite deals at the start of the week, there was no sustained bid; supposed takeout targets such as Viking sold off when they were not selected.
Watching remotely, Sam Fazeli heard a client joke that JPM should be stopped because “it’s killing a whole bunch of stocks.” The immediate damage came from downgrades and guidance, beginning with Moderna and then Lilly, which pulled related names lower despite positive meetings around science and fundamentals.
Josh Schimmer’s challenge to XBI was material: the average biotech may have risen last year even though the index ended around plus 1%. Yee explained that XBI formerly reset roughly 130 names to equal-dollar weights every 90 days, then recently moved toward a market-cap-and-liquidity formula. The result remains “a basket of haves and have-nots,” not a clean sector measure.

2. Metsera will test whether the IPO window rewards differentiated obesity assets

The IPO pipeline had “a bit of a foot off the gas pedal” through December and planned January launches. Yee inferred that two private companies acquired on the Sunday before JPM had likely considered going public; in a stronger market, they might have rejected M&A, taken a rich IPO valuation and raised again later.
Maraganore said Metsera had filed to go public and presented data supporting a once-monthly GLP-1 concept. He expected high-quality stories to get through, but the market would remain highly discriminating until investors gained better visibility on interest rates.
Fazeli’s pushback was whether an obesity company should be the year’s first IPO after intense competition and weaker sector performance. Yee conceded that “the bloom has come off the rose”: two straight quarters of Lilly disappointment and 20%–25% declines across parts of the group naturally reduced enthusiasm. Still, a successful Phase 2 or Phase 3 drug creates value; the sensitive variable is whether it starts near $600 million or $1 billion.
Fazeli kept the focus on duration: current penetration is “still a fraction of where it can go,” so quarterly disappointments do not invalidate a vast, multiyear market. Entrants must differentiate, but even Novo and Lilly can prosper. Maraganore called the sector’s growth “the beginning innings of this story.”

3. Intra-Cellular showed why derisked CNS assets command exceptional prices

J&J’s $14.6 billion agreement to acquire Intra-Cellular Therapies was described as the largest biotech acquisition since BMS–Karuna and the fourth multibillion-dollar CNS transaction in roughly a year. CAPLYTA already treats schizophrenia and bipolar depression; the requested major-depressive-disorder expansion targets a population about 10 times larger than schizophrenia.
Zohar’s clinical-development framing was deliberately unsentimental. Neuropsychiatry serves hundreds of millions of patients and approved depression drugs have often sold well, but trials face misdiagnosed or “professional” patients, inflated ratings, poor compliance, dose-selection problems and high placebo responses—especially when trial staff intervene too much. She cited roughly a 93% failure rate from preclinical development to clinical proof of concept.
Her more constructive thesis was to revisit drugs that already showed human activity but carried a problem modern technology can now solve. Xanomeline’s development through KarXT was her example: beginning with clinical evidence may improve the starting odds. The industry joke captured the payoff distribution—late-stage neuropsychiatry is difficult, “but when you have a success… it’s worth about $14 billion.” Zohar corrected: “$14.6.”
Drawing on Bruce Booth’s analysis, Maraganore said Intra-Cellular raised $1.22 billion privately and publicly, producing approximately 13× value creation in less than 12 years. He called Sharon Mates’ tenure especially notable as a founder-CEO; Yee added that the transaction confirms pharma is engaged and willing to pay for substantially derisked CNS programs.

4. Private takeouts and China licensing are replacing some public-market value creation

Yee distilled recent deal flow into three patterns: private companies being acquired, licensing replacing outright purchases, and China-originated companies or assets moving into Western pharma or newly formed U.S. vehicles. Public investors experience the first pattern as a loss: assets that might once have entered XBI are monetized before reaching them.
His explanation was valuation-driven. Public M&A candidates are well known and often priced as if a bid is coming, making them expensive; private tuck-ins carry no quoted valuation and can be smaller or less risky. GSK–IDRx and Lilly–Scorpion were discussed as examples of private exits that also exposed the difficult IPO environment.
Zohar said pharma now sources nearly one-third of external molecules from China, with roughly $6 billion of licensing upfronts flowing there over the prior year. Merck’s $112 million upfront for Hansoh’s oral GLP-1 sharply hurt Structure Therapeutics and Viking, while Roche’s $80 million upfront and roughly $1 billion in potential biobucks for an Innovent ADC showed Chinese programs moving beyond “me too” toward “me better.”
Fazeli highlighted Gilead’s $125 million upfront to LigaChem Biosciences for a preclinical oral STAT6 program, downstream of IL-4/IL-13, as well as AbbVie’s T-cell-engager deals with Simcere and AbCellera. Yee called the Gilead upfront unusually high, noting that J&J had recently paid around $30 million for a Chinese oral STAT6 program. Simcere’s multiple-myeloma trispecific targets GPRC5D, BCMA and CD3.

5. China policy offers guardrails, but little immediate protection from competition

Crowley framed biotechnology as simultaneously a public-health capability, national-security asset and engine of economic growth. Calling the competition “not xenophobia” and “not unfounded fear,” he said China has openly sought biotechnology leadership; the U.S. and its allies must advance their own lead because “the world is a better, safer, healthier and more prosperous place when we continue to lead.”
BIO’s March position on the BIOSECURE Act gave it credibility to demand “no harm to patients” and “no harm to the biomedical research establishment.” Crowley expected overwhelming House support, but Senator Rand Paul and others remained obstacles in the Senate. His likeliest route to enactment was attachment to a year-end defense appropriation after the measure fell out of the prior NDAA.
Crowley also anticipated possible tariffs, including through a national-economic-emergency declaration and the International Economic Emergency Powers Act, plus renewed restrictions on outbound investment to China. Speaker Johnson favored such limits, Senate obstacles remained and Secretary Bessent’s view was unclear. His bottom line was blunt: policy can do relatively little in the near term to arrest Chinese biotech’s growth.

6. Trial reform is the central competitive response

Crowley’s BIO Advance agenda emerged from listening sessions with more than 100 emerging-company CEOs. Their leading request was to “reimagine the clinical trial and regulatory paradigm”: medicines now cost too much, take too long and face too much uncertainty, even as company science has “leapfrogged the FDA’s ability to digest, process and evaluate” new technologies.
The proposed work spans IRBs, university contracting, CRO incentives, enrollment timelines, FDA leadership, bureaucracy and regulatory science. Crowley insisted the FDA remain the global gold standard for safety and efficacy, while using biomarkers, accelerated approval, adaptive trial designs and Bayesian statistics where appropriate—approaching urgency with an “Operation Warp Speed” mindset.
John Connolly supplied the operating comparison. A six- or 12-person cell-and-gene-therapy signal-finding study from Penn can take about two years to push through; during that interval, “20 companies” may already have run it in China. Australia, Singapore, Denmark and other countries offer more risk-based approaches, with early studies using local IRB approval under nationally administered frameworks.
Connolly proposed considering whether hospitals could assume more responsibility for early signal-finding studies, compressing timelines without abandoning oversight. Fazeli and Crowley emphasized “more carrots and fewer sticks”: make the U.S. ecosystem faster and more productive, while accepting that Chinese innovation can remain part of the global economy.

7. The policy upside extends from IRA fixes to a more receptive FTC

Crowley expected constructive engagement across parties, while reserving public opposition for policies that violate BIO’s core positions, including harmful vaccine policy. “We take Congress and the White House as we find them,” he said; politics means making friends and finding common ground, not merely opposing every official or nominee.
His 2025 agenda included hearings on the IRA’s “9 versus 13” distinction for orphan cures, the pediatric priority review voucher, addressing the R&D tax credit and manufacturing incentives through a large tax bill. He also anticipated a more receptive FTC that would recognize M&A’s role in “recycling capital and ideas” through biotechnology.
BIO planned to carry that case beyond Washington through “BIO on the American Road,” visiting emerging biotech centers almost monthly. The pilot was scheduled for Denver in early February, bringing together state leaders, members of Congress, children’s hospitals and local companies while telling human stories about patients saved by medicines—or still waiting for them.
Crowley closed more bullishly than the conference consensus: “The glass is more than half full and probably pretty clean, too.” After four difficult market years despite major scientific progress, smart changes to FDA policy, trials, tax policy and the IRA might put the industry “in a better place.” His personal explanation was simpler: “I ran a biotech company for 20 years. I’ve got to be an optimist.”

Episode 128 - January 24, 2025 Episode 126 January 10, 2025